Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
暂无分享,去创建一个
[1] G. D'Haens,et al. The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri , 2008 .
[2] D. R. Jones. Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer , 2008 .
[3] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Daniel J. Freeman,et al. 3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy , 2007 .
[5] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] L. Huo. HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial , 2007 .
[7] L. V. van't Veer,et al. Clinical application of the 70-gene profile: the MINDACT trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[9] P Bauer,et al. Multiple testing in clinical trials. , 1991, Statistics in medicine.
[10] Daniel J Sargent,et al. Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All , 2009, Journal of biopharmaceutical statistics.
[11] J. Coon,et al. Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors , 2007, Clinical Cancer Research.
[12] George Y H Chi,et al. A method for testing a prespecified subgroup in clinical trials , 2007, Statistics in medicine.
[13] Edward S. Kim,et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02 , 2007 .
[14] B. Iacopetta,et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] S. Paik,et al. Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Simon,et al. Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials , 2004, Clinical Cancer Research.
[17] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[18] F. Hirsch,et al. B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study , 2007 .
[19] R. Simon,et al. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. , 2007, Journal of the National Cancer Institute.
[20] G. Scagliotti,et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. , 2003, Lung cancer.
[21] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] David Joseph,et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer , 2000, The Lancet.
[23] E. Perez,et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Paik,et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 , 2007 .
[25] S. Taube,et al. Cancer Diagnostics , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[26] R. Simon,et al. On the efficiency of targeted clinical trials , 2005, Statistics in medicine.
[27] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Daniel J Sargent,et al. Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] D. Sargent,et al. Clinical Trial Designs for Prospective Validation of Biomarkers , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[30] P. Jänne,et al. Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2006, Clinical Cancer Research.
[31] Marc Buyse,et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial , 2006, Nature Clinical Practice Oncology.
[32] Dongsheng Tu,et al. Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.
[33] D. Slamon. Herceptin: increasing survival in metastatic breast cancer. , 2000, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[34] C. Bokemeyer,et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience , 2008 .
[35] L. V. van't Veer,et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.
[36] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[37] L. Tanoue,et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .
[38] Stella Mook,et al. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. , 2007, Cancer genomics & proteomics.
[39] S. Paik. Clinical trial methods to discover and validate predictive markers for treatment response in cancer. , 2003, Biotechnology annual review.
[40] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[41] M. Cronin,et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. , 2007, Clinical chemistry.
[42] F. Cappuzzo,et al. EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[43] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] E. Perez,et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer , 2007 .
[45] C. Bokemeyer. Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] D. Sargent,et al. Clinical Validation of Biomarkers in Cancer , 2010, Molecular Diagnostics.
[47] R. Simon,et al. Use of genomic signatures in therapeutics development in oncology and other diseases , 2006, The Pharmacogenomics Journal.
[48] Sue-Jane Wang,et al. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset , 2007, Pharmaceutical statistics.
[49] Antje Hoering,et al. Randomized Phase III Clinical Trial Designs for Targeted Agents , 2008, Clinical Cancer Research.
[50] Edward S. Kim,et al. Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine , 2008, Clinical trials.
[51] F. Cappuzzo,et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Sabine Tejpar,et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience , 2008 .
[53] B. Conley,et al. Prognostic and Predictive Markers in Cancer , 2004, Disease markers.